
HeartBeam (BEAT) Stock Forecast & Price Target
HeartBeam (BEAT) Analyst Ratings
Bulls say
HeartBeam is well-positioned to capitalize on the growing demand for portable and remote cardiac monitoring solutions, with its proprietary and patented 12-lead ECG technology and solid progress in clinical development and regulatory approvals. The recent 1Q results, including expanded commercial launch and progress in developing an extended-wear ECG patch to detect ischemia, demonstrate the company's commitment to innovation and addressing unmet needs in the market. With a multi-billion-dollar opportunity and a capital-efficient sales model, HeartBeam has the potential for strong financial performance and growth in the coming years. However, there are market development risks, including the potential for slower adoption of remote monitoring solutions, that may impact the company's growth trajectory.
Bears say
HeartBeam is currently facing numerous risks to its business, including potential failure of its device and software in clinical trials and commercial success, as well as dilution risk and the need for additional capital financing. In addition, the company's financial results for 1Q26, including a net loss of $4.7M and no revenue, are below expectations. Despite partnerships with ClearCardio and Atelier Health, revenue recognition is not expected until 2H26, and there are potential risks related to competition, regulatory approvals, and physician adoption. While HeartBeam has a strong intellectual property portfolio, ongoing innovation and enforcement may be necessary in the face of competition from larger companies in the remote cardiac monitoring space.
This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.
HeartBeam (BEAT) Analyst Forecast & Price Prediction
Start investing in HeartBeam (BEAT)
Order type
Buy in
Order amount
Est. shares
0 shares